Biotech & MedTech News
-
Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections
August 30, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to…
-
Valeo Pharma Adds Pharmaceutical Industry Veteran Kyle Steiger to Leadership Team
Kyle Steiger appointed Senior Vice-President and Chief Commercial Officer Jean-François Fournier appointed new Business Unit Head – Ophthalmology August 30, 2022…
-
Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
Agreement Provides 12-Month Exclusive Period to Agree in-Licensing Deal for Proprietary Formulation of Ketamine August 25, 2022 (Source)…
-
Hemostemix Announces Closing of UNIT Private Placement
December 31, 2020 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) announces it has closed…
-
Hemostemix Announces Unit Private Placement
August 19, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased…
-
Sixth Wave Announces Addition of Patricia Steadman, BSEE, to the Board of Directors
August 18, 2022 (Source) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth Wave” or the “Company”)…
-
Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
Licensing Partnership with Wellbeings(R) marks entry into Canadian addiction treatment and relapse prevention market August 18, 2022 (Source)…
-
Voyageur Pharmaceuticals Ltd. Announces Resignation of CFO and Appointment of Interim CFO and Shares for Debt Transaction
August 15, 2022 (Source) – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) has appointed Albert Deslauriers as…
-
Awakn Life Sciences Expands Commercial Operations into the U.S. – First Licensing Partnership Agreement with Revitalist
Awakn enters the U.S. addiction treatment and relapse prevention market August 15, 2022 (Source) – Awakn Life Sciences Corp.…
-
Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
August 12, 2022 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (“Hemostemix” or the “Company”) announces that it has closed a…
